Maxygen hematology, other news

Maxygen said its board approved a plan to liquidate and dissolve the company. The estimated shareholder payout is about $68.2-$69.6 million, or about $2.45-$2.50 per share based on 27.8 million shares outstanding as of May 31. The plan is subject to shareholder approval. Next quarter, the company expects to hold its shareholder meeting to approve the plan and make a payment of the initial liquidating distribution. At March 31, the company had $81.1 million in cash and a three-month operating loss of $2.2 million. Maxygen had a 2012 operating gain of $20.3 million. ...